To TACE or not to TACE? Lessons from a negative trial

Lancet Gastroenterol Hepatol. 2017 Aug;2(8):541-543. doi: 10.1016/S2468-1253(17)30181-4. Epub 2017 Jun 23.

Authors

Jean-Luc Raoul¹, Marine Gilabert², Xavier Adhoute³

Affiliations

¹ Department of Medical Oncology, Paoli-Calmettes Institute, 13273 Marseille, France. Electronic address: [email protected].
² Department of Medical Oncology, Paoli-Calmettes Institute, 13273 Marseille, France.
³ Department of Hepatogastroenterology, Hopital Saint Joseph, Marseille, France.

PMID: 28648802
DOI: 10.1016/S2468-1253(17)30181-4

No abstract available

Publication types

Comment

MeSH terms

Antineoplastic Agents
Carcinoma, Hepatocellular*
Chemoembolization, Therapeutic*
Combined Modality Therapy
Humans
Liver Neoplasms
Survival Rate
Treatment Outcome

Substances

Antineoplastic Agents